Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF PILL
13.73 USD -1.87 (-11.99%)
At closeNov 5, 2026, 6:03 PM EST
13.99 +0.26 +1.89%
After hours · Nov 5, 6:03 PM ET
13.73 Day range 15.84
7.75 52-week range 24.15
- YTD
- +11.63%
- 1 year
- +66.02%
- Market cap
- 32.34M
- EPS (ttm)
- 0.873814
- P/E ratio
- 15.71
- YTD return
- +11.63%
- 1-year return
- +66.02%
- Volume
- 91.89K
- Avg volume
- 52.77K
- Open
- 15.94
- Previous close
- 15.60
- Day's range
- 13.73 – 15.84
- 52-week range
- 7.75 – 24.15
5D -1.99 (-12.66%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 8.83
- 200-day average
- 7.64
About Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF
The fund invests at least 80% of its net assets in financial instruments, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index is a modified equal-weighted index that is designed to measure performance of the stocks comprising the S&P Total Market Index that are classified in the GICS pharmaceuticals sub-industry. The fund is non-diversified.
News
Top Performing Leveraged/Inverse ETFs: 06/14/2026
Trump Unveils 'Great Healthcare Plan,' Takes Aim At PBM 'Kickbacks'
Top Performing Leveraged/Inverse ETFs: 12/14/2025
Top Performing Leveraged/Inverse ETFs: 11/16/2025
Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily'
Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms
As M&A Deals Rise, Can Biotech Pharma Break Loose?
Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing
Top Performing Leveraged/Inverse ETFs: 08/17/2025
CURE: Make an Adventurous Bet on an Undervalued Sector
Your note
Sign in to keep a note on PILL — it syncs with the Stock Master app.
